![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PTG-007, a treg cell therapy, in combination with rituximab, a CD20 inhibitor, is being investigated in a phase 1/2 trial for the treatment of type-1 diabetes.
Lead Product(s): PTG-007,Rituximab
Therapeutic Area: Endocrinology Product Name: PTG-007
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Details:
PTG-007, a treg cell therapy, in combination with rituximab, a CD20 inhibitor, is being investigated in a phase 1/2 trial for the treatment of type-1 diabetes.
Lead Product(s): PTG-007,Rituximab
Therapeutic Area: Endocrinology Product Name: PTG-007
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024